title: A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time.
abstract: OBJECTIVE
  To compare in a phase III study the loco-regional control, disease-free survival and overall survival induced by an accelerated regimen (AF) as compared with conventional regimen (CF) and to analyze the early and late post-radiation morbidity in both arms.
  
  
  METHODS
  Patients with age < or = 75, WHO 0-1, suitable for a radical course of radiotherapy T1-T3, N0, M0, stage of glottic and supraglottic laryngeal cancer were randomized to either CF: 66Gy given in 33 fractions over 45 days or AF: 66Gy given in 33 fractions over 38 days (2 fractions every Thursday). A total of 395 patients were included from 05.1995 to 12.1998.
  
  
  RESULTS
  Early toxicity: At the end of radiotherapy patients treated with AF complained for more severe reactions than patients treated with CF. In 8 weeks after treatment completion patients treated with AF complained only for more severe pain on swallowing (P=0.027). In 4 months after treatment completion all types of toxicity except for skin teleangiectasia (P=0.001) were similar in the two groups. Loco-regional control: comparison between CF and AF showed no difference in terms of loco-regional control (P=0.37).
  
  
  CONCLUSIONS
  The improvement in AF in terms of loco-regional control is estimated to be 3-5% in comparison with conventional regimen and is not significant. The intensity of reactions after 4 months was similar in both arms, what suggests the possibility of further shortening of the overall time by few days or enhancing the total dose within the limits of acceptable morbidity.
authors.affiliation: Center of Oncology-Institute, Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Hliniak
authors.forename: B
authors.initials: B
authors.lastname: Gwiazdowska
authors.forename: Z
authors.initials: Z
authors.lastname: Szutkowski
authors.forename: E
authors.initials: E
authors.lastname: Kraszewska
authors.forename: P
authors.initials: P
authors.lastname: Kukolowicz
authors.forename: A
authors.initials: A
authors.lastname: Jarzabski
authors.forename: B
authors.initials: B
authors.lastname: Sochacka
authors.forename: M
authors.initials: M
authors.lastname: Mazurkiewicz
authors.forename: K
authors.initials: K
authors.lastname: Paprota
authors.forename: W
authors.initials: W
authors.lastname: Oliskiewicz
authors.forename: O
authors.initials: O
authors.lastname: Zadrozna
authors.forename: P
authors.initials: P
authors.lastname: Milecki
authors.forename: M
authors.initials: M
authors.lastname: Kubiak
authors.forename: L
authors.initials: L
authors.lastname: Czopkiewicz
authors.forename: M
authors.initials: M
authors.lastname: Jagas
authors.forename: S
authors.initials: S
authors.lastname: Góźdź
authors.forename: A
authors.initials: A
authors.lastname: Wieczorek
authors.forename: A
authors.initials: A
authors.lastname: Woytowicz
authors.forename: B
authors.initials: B
authors.lastname: Cisowska
authors.forename: H
authors.initials: H
authors.lastname: Magdziarz
authors.forename: S
authors.initials: S
authors.lastname: Nowakowski
authors.forename: W
authors.initials: W
authors.lastname: Kośniewski
authors.forename: I
authors.initials: I
authors.lastname: Laskosz
authors.forename: A
authors.initials: A
authors.lastname: Serafin
authors.forename: E
authors.initials: E
authors.lastname: Gradoń
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome